Almac Group Receives Annual Industrial Award from the Institute of Chemistry of Ireland

Professor Tom Moody accepts accolade on behalf of Biocatalysis Team

Craigavon, N.I., 05 December 2017Almac Group, the global contract development and manufacturing organisation is delighted to announce Professor Tom Moody, VP Technology Development & Commercialisation at Almac & Arran Chemical Company, has received the prestigious Institute of Chemistry of Ireland Industrial Chemistry Award 2017.

Read More

IABCN Ambassador Club Member & Former Taoiseach Award Honoree, John Mullen of Apple Vacations, buys Carton House resort
The Irish Times 

The Nama-backed sale of Carton House hotel and golf resort near Maynoothin Co Kildare was completed on Thursday with a closing price believed to be about €57 million.

The resort hotel was sold by the Mallaghan and Kelly families to Irish American businessman John Mullen.

Mr Mullen’s parents are from Co Mayo and this will be a personal investment and his first in Ireland. The 668-acre estate was put on the market in July with the consent of Nama. The 165-bedroom estate also includes two golf courses and extensive sports and spa facilities.

Read More

There is bipartisan support in Washington for Irish position on the Border
By: Congressman Brendan F. Boyle and Congressman Brian Fitzpatrick
The Irish Times

As bipartisan members of the Congress of the United States, as well as the House Foreign Affairs Committee, we are deeply committed to preserving the peace and stability achieved for the six counties of Northern Ireland and the Republic of Ireland under the Good Friday Agreement.

Read More

Almac Discovery publishes USP7 inhibitors from UbiPlexTM Platform

Craigavon, N.I., UK, 4 December 2017Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, has today published its findings on the discovery and characterisation of highly potent, selective and reversible inhibitors of ubiquitin-specific protease 7 (USP7) in the journal Nature Chemical Biology. Despite substantial efforts over nearly two decades, the development of validated deubiquitinase (DUB) inhibitors that exhibit drug like properties and a well-defined mechanism has proven particularly challenging—overall, Almac’s findings successfully demonstrate the tractability and druggability of DUBs, and provide important tools for additional target validation studies.

Read More